212 related articles for article (PubMed ID: 22941471)
1. Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan.
Sato D; Sato Y; Masuda S; Kimura H
Int J Clin Pharm; 2012 Dec; 34(6):917-24. PubMed ID: 22941471
[TBL] [Abstract][Full Text] [Related]
2. Effects of a sitagliptin safety alert on prescription behaviour for oral antihyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan.
Sato D; Sato Y; Masuda S; Kimura H
Drug Saf; 2013 Aug; 36(8):605-15. PubMed ID: 23700263
[TBL] [Abstract][Full Text] [Related]
3. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
Umayahara R; Yonemoto T; Kyou C; Morishita K; Ogawa T; Taguchi Y; Inoue T
Endocr J; 2014; 61(12):1163-70. PubMed ID: 25168659
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database].
Umetsu R; Nishibata Y; Abe J; Suzuki Y; Hara H; Nagasawa H; Kinosada Y; Nakamura M
Yakugaku Zasshi; 2014; 134(2):299-304. PubMed ID: 24492232
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for adverse symptoms during dipeptidyl peptidase-IV inhibitor therapy: a questionnaire-based study carried out by the Japan Pharmaceutical Association Drug Event Monitoring project in Kumamoto Prefecture.
Kajiwara A; Saruwatari J; Sakata M; Morita K; Kita A; Oniki K; Yamamura M; Murase M; Koda H; Hirota S; Ishizuka T; Nakagawa K
Drug Saf; 2013 Oct; 36(10):981-7. PubMed ID: 23743694
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
Herman GA; Mistry GC; Yi B; Bergman AJ; Wang AQ; Zeng W; Chen L; Snyder K; Ruckle JL; Larson PJ; Davies MJ; Langdon RB; Gottesdiener KM; Wagner JA
Br J Clin Pharmacol; 2011 Mar; 71(3):429-36. PubMed ID: 21284702
[TBL] [Abstract][Full Text] [Related]
7. Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature.
Furukawa S; Kumagi T; Miyake T; Ueda T; Niiya T; Nishino K; Murakami S; Murakami M; Matsuura B; Onji M
Endocr J; 2012; 59(4):329-33. PubMed ID: 22277726
[TBL] [Abstract][Full Text] [Related]
8. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
[TBL] [Abstract][Full Text] [Related]
9. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
10. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.
Vaduganathan M; Singh A; Sharma A; Januzzi JL; Scirica BM; Butler J; Zannad F; McGuire DK; Cannon CP; Bhatt DL
Am J Cardiol; 2020 May; 125(10):1577-1581. PubMed ID: 32245636
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
[TBL] [Abstract][Full Text] [Related]
13. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM
Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes.
Yuan G; Jia J; Zhang C; Yu S; Dong S; Ye J; Zhu T; Tang B; Qian W; Wang D; Yang L; Zhou L; Mao C
Endocr J; 2014; 61(5):513-21. PubMed ID: 24621778
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
17. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
[TBL] [Abstract][Full Text] [Related]
18. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
[TBL] [Abstract][Full Text] [Related]
19. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies.
Round EM; Engel SS; Golm GT; Davies MJ; Kaufman KD; Goldstein BJ
Drugs Aging; 2014 Mar; 31(3):203-14. PubMed ID: 24510656
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin: a review.
Subbarayan S; Kipnes M
Expert Opin Pharmacother; 2011 Jul; 12(10):1613-22. PubMed ID: 21651449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]